India, June 27 -- Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., has announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili™ (aflibercept), a biosimilar to Eylea® (aflibercept). The approval, received on June 26, 2025, covers both vial and prefilled syringe presentations (2 mg/0.05 mL), and marks the first approval of an Eylea biosimilar in Canada. The company plans to launch the product in the Canadian market on July 4, 2025.
Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of several serious eye conditions, including neovascular (wet) age-related macular degeneration (AMD), macular edema due to central and branch...